Thorold, Canada
Thorold, Canada

Time filter

Source Type

Hamzeh-Mivehroud M.,Tabriz University of Medical Sciences | Mahmoudpour A.,Tabriz University of Medical Sciences | Mahmoudpour A.,Norgen Biotek Corporation | Dastmalchi S.,Tabriz University of Medical Sciences
Chemical Biology and Drug Design | Year: 2012

Peptide phage display, a powerful method for ligand identification, was used to identify new peptide ligands for epidermal growth factor receptor. A-431 cells expressing epidermal growth factor receptor were used as the matrix in a cell-based subtractive biopanning approach using a 7-mer peptide displaying phage library. Two novel peptide ligands were identified and tested for their affinities and functional effects on epidermal growth factor receptor. The identified peptides were able to inhibit the epidermal growth factor-induced phosphorylation of epidermal growth factor receptor in a concentration-dependent manner. The results of affinity binding experiments showed that the natural ligand, that is epidermal growth factor, was able to inhibit competitively the binding of peptide-bearing phage to epidermal growth factor receptor expressing A-431 cells. Molecular modeling studies were used to calculate the free energies for the binding of peptides to the receptor-binding site as well as proposing the interaction modes for this binding. The calculated values for the binding energies were found to be similar to our experimental data and those of previously reported studies. © 2011 John Wiley & Sons A/S.


Kim W.-S.,Norgen Biotek Corporation | Haj-Ahmad Y.,Norgen Biotek Corporation | Stobbs L.W.,Southern Crop Protection and Food Research Center | Greig N.,Southern Crop Protection and Food Research Center
Canadian Journal of Plant Pathology | Year: 2015

Early viroid detection in chrysanthemum cultivars depends on both an efficient RNA extraction method as well as a sensitive detection assay. In this study, we evaluated RNA purification methods and optimized a one-step RT-qPCR assay for the detection of Chrysanthemum stunt viroid (CSVd). Three commercially available RNA extraction technologies (silica and silicon carbide spin column as well as the phenol/chloroform extraction) were compared for efficacy in CSVd detection sensitivity. We found a 10- to 50-fold improvement in CSVd detection sensitivity when using silicon carbide (SiC) spin columns to purify RNA compared with the silica-based column or the traditional phenol/chloroform extraction method. To optimize detection sensitivity and reduce detection time, a commercial CSVd end-point PCR primer set was adapted to a SYBR Green based one-step RT-qPCR assay. Standard curve analysis estimated that the limit of detection was about 54 CSVd copies and the specificity test against six related viroids showed no cross-reactivity. As a part of the validation, the one-step RT-qPCR detection system was compared with RT-PCR to detect CSVd in both randomly selected greenhouse plants and mechanically inoculated chrysanthemum varieties. Cultivars selected from a commercial greenhouse with >50% infection levels were tested for CSVd presence. Cultivars Pelee, Puma and Shamrock tested positive by both the one step RT-qPCR and RT-PCR but CSVd was not detected in Icecap and Snowball. In mechanical inoculation studies, CSVd was detected in 5 of 6 chrysanthemum cultivars - Chesapeake, Durango, Juneau, Pelee and Viron but not in Pueblo. No differences in detection were evident between the RT-qPCR and RT-PCR methods. © 2015 The Canadian Phytopathological Society.


Simkin M.,Brock University | Simkin M.,Norgen Biotek Corporation | Abdalla M.,Norgen Biotek Corporation | El-Mogy M.,Norgen Biotek Corporation | And 2 more authors.
Epigenomics | Year: 2012

TP53 is a tumor-suppressor gene coding for p53, a protein responsible for cell-cycle arrest and DNA repair. Smoking has been demonstrated to lead to the methylation of tumor-suppressor genes in noncancerous lung biopsy tissues of smokers, and in bodily fluids, promoter hypermethylation occurs very early in the progression of cancer. Thus, DNA methylation changes may be initiated long before cells become cancerous. As this association has never been explored in young, healthy individuals, we decided to look at DNA isolated from urine and saliva samples taken from young male and female smoking and nonsmoking participants. While p53 methylation was not found in any of the samples tested, differences in DNA concentration between the two groups may shed light on the timing of epigenetic alterations, as well as better explain why the negative impact of smoking is not often found in young, healthy adults. © Future Medicine Ltd.


Provided is a nucleic acid preservative comprising at least one reducing agent, at least one chaotropic substance, at least one polyamine substance and at least one chelating agent and uses thereof, and a method for the preservation of nucleic acids in a biological sample. Further provided are kits for use in the preservation of nucleic acids in a biological sample, and more particularly, a blood sample.


Patent
Norgen Biotek Corporation | Date: 2011-07-22

The present invention provides a device for the concentration of one or more target analytes contained in a urine sample. The device comprises a tube comprising an upper portion defining an opening for receiving the urine sample and a lower tapered portion terminating in collection reservoir. The tube contains a predetermined amount of a particulate binding agent which specifically binds the one or more target analytes and of a predetermined amount of a binding buffer. The device comprises means for seating the opening of the tube. The present invention further provides methods and kits for concentrating one or more target analytes in murine sample.


Disclosed are microRNA biomarkers and use thereof for screening and diagnosis of prostate cancer and benign prostatic hyperplasia. This invention provides a method for screening for prostate cancer in a subject involving the steps of: (a) assaying the miRNA expression level in a test sample from the subject to be screened for prostate cancer; (b) comparing the assayed miRNA expression level of the subject to the miRNA expression level in a normal sample providing a control relative to the test sample of the subject; and (c) computing the differential expression of the miRNA from the subject, wherein the over-expression of miR-1825 or under the expression of miR-484 is indicative of prostate cancer. In another aspect, provided is a method for screening for benign prostatic hyperplasia in a subject involving the steps of: (a) assaying the miRNA expression level in a test sample from the subject to be screened for benign prostatic hyperplasia; (b) comparing the assayed miRNA expression level of the subject to the miRNA expression level in a normal sample providing a control relative to the test sample of the subject; and (c) computing the differential expression of the miRNA from the subject, wherein the under expression of miR-498 is indicative of benign prostatic hyperplasia.


Patent
Norgen Biotek Corporation | Date: 2016-05-06

Disclosed is a method for the isolation of extracellular vesicles, including exosomes, from a liquid sample, the method comprising the steps of: adjusting the pH of a liquid sample comprising extracellular vesicles to a preselected, binding pH; contacting the liquid sample with silicon carbide, wherein at the preselected, binding pH, the extracellular vesicles bind to the silicon carbide; and eluting the bound extracellular vesicles from the silicon carbide. The liquid samples can comprise bodily fluids. Further disclosed is a method for producing a liquid sample, substantially depleted of extracellular vesicles, including exosomes.


Patent
Norgen Biotek Corporation | Date: 2016-07-19

Provided are methods and columns employing a solid support comprising silica and silicon carbide for the isolation and purification of nucleic acids, and in particular, the isolation and purification of both high and low molecular weight RNA.


Patent
Norgen Biotek Corporation | Date: 2014-04-30

The present invention provides a device for the concentration of one or more target analytes contained in a urine sample. The device comprises a tube comprising an upper portion defining an opening for receiving the urine sample and a lower tapered portion terminating in a collection reservoir. The tube contains a predetermined amount of a particulate binding agent which specifically binds the one or more target analytes and of a predetermined amount of a binding buffer. The device comprises means for sealing the opening of the tube. The present invention further provides methods and kits for concentrating one or more target analytes in a urine sample.


PubMed | University of Arkansas for Medical Sciences and Norgen Biotek Corporation
Type: | Journal: International journal of nephrology | Year: 2016

Diabetic nephropathy (DN) and diabetic retinopathy (DR) are major complications of type 1 and type 2 diabetes. DN and DR are mainly caused by injury to the perivascular supporting cells, the mesangial cells within the glomerulus, and the pericytes in the retina. The genes and molecular mechanisms predisposing retinal and glomerular pericytes to diabetic injury are poorly characterized. In this study, the genetic deletion of proteasome activator genes, PA28

Loading Norgen Biotek Corporation collaborators
Loading Norgen Biotek Corporation collaborators